Remission in schizophrenia: Applying recent consensus criteria to refine the concept

Schizophrenia Research

Volumn 96, Issue 1-3, 2007, Pages 223-231

  Lasser, Robert A ^a   Nasrallah, Henry ^b   Helldin, Lars ^c   Peuskens, Joseph ^d   Kane, John ^e   Docherty, John ^f   Toledo Tronco, Anselmo ^g  

^a Neuliance   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c NU Health Care Trollhattan   (Sweden)

^d University Centrum St Jozef   (Belgium)

^e ZUCKER HILLSIDE HOSPITAL   (United States)

^f Univ S Carolina Sch Med Vice P   (United States)

^g NONE   (Philippines)

Author keywords

Cognition; Negative symptoms; Psychosocial functioning; Quality of life; Remission; Schizophrenia

Indexed keywords

COGNITIVE DEFECT; COMORBIDITY; CONSENSUS DEVELOPMENT; CORRELATION ANALYSIS; DISEASE SEVERITY; DISORIENTATION; HEALTH CARE COST; HUMAN; NEGATIVE SYNDROME; NEUROPSYCHIATRY; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; REMISSION; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; COGNITION; HUMANS; REMISSION, SPONTANEOUS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 34848918163     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.05.003     Document Type: Review

References (26)

1. Amminger G.P., Resch F., Mutschlechner R., Friedrich M.H., and Ernst E. Premorbid adjustment and remission of positive symptoms in first-episode psychosis. Eur. Child Adolesc. Psychiatry 6 4 (1997) 212-218
2. Andreasen N., Carpenter W., Kane J., Lasser R., Marder S., and Weinberger D. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 162 2 (2005) 441-449
3. Angermeyer M.C., Kuhn L., and Goldstein J.M. Gender and the course of schizophrenia: differences in treated outcomes. Schizophr. Bull. 16 2 (1990) 293-307
4. Ballenger J.C., Davidson J.R., Lecrubier Y., Nutt D.J., Baldwin D.S., den Boer J.A., Kasper S., and Shear M.K. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J. Clin. Psychiatry 59 Suppl 8 (1998) 47-54
5. Ballenger J.C., Davidson J.R., Lecrubier Y., Nutt D.J., Borkovec T.D., Rickels K., Stein D.J., and Wittchen H.U. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J. Clin. Psychiatry 62 Suppl 11 (2001) 53-58
6. Eaton W.W., Thara R., Federman E., and Tien A. Remission and relapse in schizophrenia: the Madras Longitudinal Study. J. Nerv. Ment. Dis. 86 6 (1998) 357-363
7. Frank E., Prien R., Jarrett R., Keller M., Kupfer D., Lavori P., Rush A., and Weissman M. Conceptualization and rationale for consensus definitions of terms in major depresive disorder. Remission, recovery, relapse and recurrence. Arch. Gen. Psychiatry 48 (1991) 851-855
8. Gharabawi G., Bossie C., Rodriguez S., Turkoz I., and Simpson G. Exploring the evidence for a relationship between symptomatic remission and improvement in functioning in patients with schizophrenia. Poster Presented at the 44th Annual Meeting of the American College of Neuropsychopharmacology, Decemeber 11-15, Hawaii (2005)
9. Goff D.C. Pharmacologic implications of neurobiological models of schizophrenia. Harv. Rev. Psychiatry 13 6 (2005) 352-359
10. Helldin L., Kane J.M., Karilampi U., Norlander T., and Archer T. Remission and cognitive ability in a cohort of patients with schizophrenia. J. Psychiatr. Res. 40 8 (2006) 738-745
11. Ho B.C., Andreasen N.C., Flaum M., Nopoulos P., and Miller D. Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia. Am. J. Psychiatry 157 5 (2000) 808-815
12. Johnson D.A., Pasterski G., Ludlow J.M., Street K., and Taylor R.D. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr. Scand. 67 5 (1983) 339-352
13. Kane J. Progress defined - short-term efficacy, long-term effectiveness. Int. Clin. Psychopharmacol. 16 1 (2001) S1-S8
14. Kissling W., Heres S., Lloyd K., Sacchetti E., Bouhours P., Medori R., and Llorca P. Direct transition to long-acting risperidone - analysis of long-term efficacy. J. Psychopharmacol. 19 5 Suppl (2005) 15-21
15. Kraepelin E. Dementia Praecox and Paraphrenia. Translated and Edited by RB Barclay (1919)
16. Lasser R.A., Bossie C.A., Gharabawi G.M., and Kane J.M. Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr. Res. 77 2-3 (2005) 215-227
17. Liberman R., Kopelowicz A., Ventura J., and Gutkind D. Operational criteria and factors related to recovery from schizophrenia. Int. Rev. Psychiatry 14 (2002) 256-272
18. Lieberman J., Bogerts B., and Degreef G. Qualitative assessment of brain morphology in acute and chronic schizophrenia. Am. J. Psychiatry 149 (1992) 784-794
19. Lieberman J., Jody D., Geisler S., Alvir J., Loebel A., Szymanski S., Woerner M., and Borenstein M. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch. Gen. Psychiatry 50 5 (1993) 369-376
20. Lieberman J.A., Perkins D., Belger A., Chakos M., Jarskog F., Boteva K., and Gilmore J. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol. Psychiatry. 50 11 (2001) 884-897
21. Lieberman J.A., Phillips M., Gu H., Stroup S., Zhang P., Kong L., Ji Z., Koch G., and Hamer R.M. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 28 5 (2003) 995-1003
22. Marshall M., Lewis S., Lockwood A., Drake R., Jones P., and Croudace R. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch. Gen. Psychiatry 62 9 (2005) 975-983
23. Molina V., Sanz J., Sarramea F., Benito C., and Palomo T. Lower prefrontal gray matter volume in schizophrenia in chronic but not in first episode schizophrenia patients. Psychiatry Res. 131 1 (2004) 45-56
24. van Os J., Drukker M., Campo J., Meijer J., Bak M., and Delespaul P. Validation of remission criteria for remission. Am. J. Psychiatry 163 11 (2006) 2000-2002
25. Wyatt R. Neuroleptics and the natural course of schizophrenia. Schizophr. Bull. 17 (1991) 325-351
26. Yen C.F., Chen C.S., Yeh M.L., Yen J.Y., Ker J.H., and Yang S.J. Comparison of insight in patients with schizophrenia and bipolar disorder in remission. J. Nerv. Ment. Dis. 190 12 (2002) 847-849